Izotropic Announces AGM Results

Rhea-AI Summary

Izotropic (OTCQB: IZOZF) announced results of its Annual General and Special Meeting held on December 29, 2025. Shareholders approved the election of nominees to a five-member board, ratified the re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP, and approved a by-law amendment reducing the shareholder quorum requirement from 20% to at least 1% of issued voting shares. The quorum change preserves majority voting for decisions and was proposed in response to persistent mail delays, posting disruptions, and delays affecting shareholders using self-managed trading platforms. The company thanked shareholders for their participation and support.

Positive

• Board size set at five directors (elected Dec 29, 2025)
• Auditor re-appointed Dale Matheson Carr-Hilton LaBonte LLP
• Quorum lowered from 20% to at least 1%, easing vote completion

Negative

• Quorum cut to ≥1% may allow key votes with minimal shareholder turnout
• Reduced participation risks perceived governance weaker by some investors

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025.

Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, dated November 27, 2025, were approved by the requisite majority of votes cast at the meeting.

The primary annual and special matters acted upon were the approval of all nominees to sit as directors of the corporation for the ensuing year with the number of directors set at five (5), the approval of the re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP, and the amendment of the Company's By-Laws to reduce the quorum requirement from 20% to at least 1% of the issued voting shares, with decisions continuing to require majority approval. This amendment was brought forward in response to persistent challenges faced by many public companies, including mail delays, posting disruptions, and delays experienced by shareholders using self-managed trading platforms in receiving voting packages.

The Company thanks all shareholders for their participation and ongoing support.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR+ at sedarplus.ca.

Forward-Looking Statements: This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale. Podcast episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279326

FAQ

What did Izotropic (IZOZF) shareholders approve at the December 29, 2025 AGM?

Shareholders approved a five-member board slate, re-appointed Dale Matheson Carr-Hilton LaBonte LLP as auditor, and amended the by-laws to lower quorum to at least 1%.

When did Izotropic hold its Annual General and Special Meeting for 2025?

The meeting was held on December 29, 2025.

How did Izotropic change its by-law quorum requirement in December 2025?

The by-law was amended to reduce quorum from 20% to at least 1% of issued voting shares, while keeping majority vote requirements.

Who was re-appointed as Izotropic's auditor at the 2025 AGM (IZOZF)?

Dale Matheson Carr-Hilton LaBonte LLP was re-appointed as auditor.

What is the potential shareholder impact of Izotropic’s quorum reduction (IZOZF)?

The change makes it easier to reach quorum and conclude votes but may result in decisions with low shareholder turnout.